EWEdgewise Therapeutics EWTX · NASDAQ
$39.99 +0.86% (+$0.34)
- Market cap
- $4.30B
- Enterprise value
- $4.23B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -48.5%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.28
- Free float
- 76.1%
About the company
Edgewise Therapeutics, Inc. is a biotechnology company based in the United States that focuses on the development of therapeutic drugs for rare genetic diseases. The company specializes in innovative approaches in gene therapy and targets conditions such as Duchenne muscular dystrophy and other muscle disorders. Edgewise Therapeutics uses advanced scientific methods to develop drugs with the potential to significantly improve the quality of life for patients suffering from these serious and currently challenging-to-treat conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
Kevin Koch
Employees
127
Headquarters
Boulder
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number